{"id":473938,"date":"2021-04-08T17:03:18","date_gmt":"2021-04-08T21:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473938"},"modified":"2021-04-08T17:03:18","modified_gmt":"2021-04-08T21:03:18","slug":"the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/","title":{"rendered":"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LOS ANGELES, April  08, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n2JoCqz5IjRjn4I-umrv5cyScK9ez7aqG2nJpW2RVctWgPQteZ56m9YedhYZvzkJEVXkFwN-qK4ZzRQB04iMOMz2PIM4eRmSZHquB2mr-NkTS1t_1GRBjBv5a1rbbyfg\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">The Law Offices of Frank R. Cruz<\/a> continues its investigation on behalf of FibroGen Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bEBUCLdLICB4Ln9YOud4YlIIdWEU1fGVXxk0VLdPyNs-yObssybbDrhPzqlaW_9rZADTpJXC4B5RuPtdlw59BA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">FGEN<\/a>) investors concerning the Company and its officers\u2019 possible violations of federal securities laws.<\/p>\n<p>If you are a shareholder who suffered a loss, click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hez6K5OVE3GOJixQtf__SoQzSXQwL2dsiceMDzFsGr3JBk15_4dIARmOESykqjiWg28AVWfIOVAsIXedBSbY3i4GU8kZkYdTq3MQNqSd0PA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> to participate.<\/p>\n<p>On April 6, 2021, after the market closed, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety analyses \u201cincluded post-hoc changes to the stratification factors.\u201d FibroGen further revealed that, based on analyses using the pre-specified stratification factors, the Company \u201ccannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.\u201d<\/p>\n<p>On this news, the Company\u2019s share price fell $14.90, or 43%, to close at $19.74 per share on April 7, 2021, thereby injuring investors.<\/p>\n<p>Follow us for updates on Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EKRZTcdCNUBmfmmszrgoMfbXNxflm3nkoCgHm9Lpt1Ar_XqKzbbMcpiArIPNQyrE11UA7plJ0xmUHHfvUR-r1jc5WHNJrsZSVqlkgaIhwF4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">twitter.com\/FRC_LAW<\/a>.<\/p>\n<p>If you purchased FibroGen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qM3kOr2KspBcCBgsQGDHwf0zGph0ytcBpmWWSJfmHGMKn2fyJvKGzPglzzYd_fZEszGlcf5CXsWGmrDGUq6oloXEmAaVTkD3RG1U_3ZMc7w=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@frankcruzlaw.com<\/a>, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xKKmqZAl1RWW29tR0rTLkqYm19hkmwWRweokGbQjMlN1nVqf6F2yPfPA70CBseCDwMs0zHpnCkLRiEdV2z0Y2pIOB2FU4nhe8WaYCNwiiy8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.frankcruzlaw.com<\/a>.\u00a0\u00a0 If you inquire by email please include your mailing address, telephone number, and number of shares purchased.<\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>The Law Offices of Frank R. Cruz, Los Angeles<br \/>Frank R. Cruz, 310-914-5007<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sKgtTWua9VFxLMAT4zXt7olr62RwH7TDdZWwQlDpiYLsNvADSQmqGIQG6M2wCuzLGS1woS5IF530jjR8OwkZ2Fz2Oc8vuhDptzWfsqNch88=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">fcruz@frankcruzlaw.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xKKmqZAl1RWW29tR0rTLkqc4_f8lEVyE5NGrovGwiW75YprtTHQ_s5hJ-eVcw0yjfwgWWz5rnbFHmBkeJw5PqePxC8JspS4EkkXWZMpHXW8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.frankcruzlaw.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/872f7870-485a-4951-b6ea-6a6a9f8e65a7\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, April 08, 2021 (GLOBE NEWSWIRE) &#8212; The Law Offices of Frank R. Cruz continues its investigation on behalf of FibroGen Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) investors concerning the Company and its officers\u2019 possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 6, 2021, after the market closed, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety analyses \u201cincluded post-hoc changes to the stratification factors.\u201d FibroGen further revealed that, based on analyses using the pre-specified &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473938","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, April 08, 2021 (GLOBE NEWSWIRE) &#8212; The Law Offices of Frank R. Cruz continues its investigation on behalf of FibroGen Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) investors concerning the Company and its officers\u2019 possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 6, 2021, after the market closed, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety analyses \u201cincluded post-hoc changes to the stratification factors.\u201d FibroGen further revealed that, based on analyses using the pre-specified &hellip; Continue reading &quot;The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T21:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors\",\"datePublished\":\"2021-04-08T21:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/\",\"name\":\"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=\",\"datePublished\":\"2021-04-08T21:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/","og_locale":"en_US","og_type":"article","og_title":"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Market Newsdesk","og_description":"LOS ANGELES, April 08, 2021 (GLOBE NEWSWIRE) &#8212; The Law Offices of Frank R. Cruz continues its investigation on behalf of FibroGen Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) investors concerning the Company and its officers\u2019 possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 6, 2021, after the market closed, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety analyses \u201cincluded post-hoc changes to the stratification factors.\u201d FibroGen further revealed that, based on analyses using the pre-specified &hellip; Continue reading \"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T21:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors","datePublished":"2021-04-08T21:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/","name":"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=","datePublished":"2021-04-08T21:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzkwNSM0MTEyNDUyIzIxOTQyMzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-law-offices-of-frank-r-cruz-continues-its-investigation-of-fibrogen-inc-fgen-on-behalf-of-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473938"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473938\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}